FrancophonIA/ELRC3.0 huggingface dataset:
English: heartburn (reflux of food from the stomach), blood in the stool
Croatian: želuca ili jednjaka, bol u donjem dijelu trbuha, nelagoda u trbuhu, žgaravica (povrat hrane iz želuca), krv u stolici
English: Petechiae,
Croatian: omaglica,
English: • decrease in blood sodium, magnesium or calcium, increase in blood sugar
Croatian: Česte nuspojave (mogu se javiti u manje od 1 na 10 osoba): • smanjena razina natrija, magnezija ili kalcija u krvi, povišena razina šećera u krvi
English: Table 8 Key efficacy results for AIO KRK study XELOX + bevacizumab
Croatian: Tablica 8 Ključni podaci o djelotvornosti ispitivanja AIO KRK
English: Hepatic function abnormal
Croatian: Oštećenje jetrene funkcije
English: Reduced dose 500 mg/m2
Croatian: 500 mg/m2
English: Package leaflet: Information for the user Capecitabine Teva 150 mg film-coated tablets Capecitabine Teva 500 mg film-coated tablets capecitabine
Croatian: Kapecitabin Teva 150 mg filmom obložene tablete Kapecitabin Teva 500 mg filmom obložene tablete kapecitabin
English: Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.
Croatian: U 50% bolesnika je uočeno da kapecitabin može inducirati pojavu proljeva.
English: • nerve pain
Croatian: • bol duž živca
English: Dose level 1000 mg/m2 (twice daily)
Croatian: (1000 mg/m dvaput dnevno tijekom 14 dana) i oksaliplatina (130 mg/m
English: What is Ocaliva and what is it used for?
Croatian: Što je Ocaliva i za što se koristi?
English: Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.
Croatian: Svake godine Agencija pregledava sve nove informacije koje postanu dostupne te se ovaj sažetak po potrebi ažurira.
English: This overview was last updated in 03-2018.
Croatian: Pregled je posljednji put ažuriran u 03. 2018.
English: Ocaliva (obeticholic acid)
Croatian: Ocaliva (obetikolna kiselina)
English: After a few months, if Ocaliva is well tolerated the dose can be increased.
Croatian: Nakon par mjeseci, ako se lijek Ocaliva dobro podnosi, doza se može povećati.
English: What measures are being taken to ensure the safe and effective use of Ocaliva?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Ocaliva?
English: Further information on Ocaliva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Dodatne informacije o lijeku Ocaliva nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The recommended starting dose is 5 mg once a day or 5 mg once a week, depending on the patient's degree of liver impairment (which should be determined before starting treatment with Ocaliva).
Croatian: Preporučena početna doza je 5 mg jedanput na dan ili 5 mg jedanput tjedno, ovisno o stupnju oštećenja jetre bolesnika (koju je potrebno utvrditi prije započinjanja terapije lijekom Ocaliva).
English: Ocaliva received a marketing authorisation valid throughout the EU on 12 December 2016.
Croatian: Lijek Ocaliva dobio je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 12. prosinca 2016.
English: Why is Ocaliva authorised in the EU?
Croatian: Zašto je lijek Ocaliva odobren u EU-u?
English: Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Ovdje možete pronaći dodatne informacije o uvrštenju lijekova za rijetke bolesti: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Itching is also the most common side effect that can lead to discontinuation of treatment.
Croatian: Svrbež je također najčešća nuspojava koja može dovesti do prekida liječenja.
English: The European Medicines Agency therefore decided that Ocaliva's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Ocaliva nadmašuju s njim povezane rizike te da se može izdati odobrenje za njegovu primjenu u EU-u.
English: The study showed that Ocaliva was more effective than placebo at reducing the blood levels of bilirubin and ALP: levels decreased by the required amount in 47% (34 out of 73) of patients treated with Ocaliva 10 mg and in 46% (32 out of 70) of patients treated with increasing doses of Ocaliva (from 5 mg up to 10 mg), compared with 10% (7 out of 73) of patients on placebo.
Croatian: Ispitivanje je pokazalo da je lijek Ocaliva učinkovitiji od placeba u snižavanju razina bilirubina i ALP-a u krvi: razine su snižene za potrebne vrijednosti u 47 % (34 od 73) bolesnika liječenih dozom lijeka Ocaliva od 10 mg i u 46 % (32 od 70) bolesnika liječenih povećanim dozama lijeka Ocaliva (od 5 mg do 10 mg), u usporedbi s 10 % (7 od 73) bolesnika koji su primali placebo.
English: Ocaliva has been given ‘conditional authorisation'.
Croatian: Za lijek Ocaliva izdano je „uvjetno odobrenje”.
English: However, the clinical benefits of Ocaliva need to be demonstrated in further studies.
Croatian: Međutim, kliničke koristi od lijeka Ocaliva potrebno je dokazati u daljnjim ispitivanjima.
English: What are the risks associated with Ocaliva?
Croatian: Koji su rizici povezani s lijekom Ocaliva?
English: Since Ocaliva has been granted a conditional authorisation, the company that markets Ocaliva will provide additional data from two studies to confirm the effectiveness and safety of the medicine.
Croatian: Budući da je lijek Ocaliva dobio uvjetno odobrenje, tvrtka koja stavlja lijek Ocaliva u promet mora dostaviti dodatne podatke iz dvaju ispitivanja kako bi se utvrdila učinkovitost i sigurnost lijeka.
English: Patients with primary biliary cholangitis have limited treatment options.
Croatian: Bolesnici s primarnim bilijarnim kolangitisom imaju ograničene mogućnosti liječenja.
English: The safety profile of the medicine was considered to be favourable, with side effects that were tolerable and manageable with supportive treatment (e.g. for itching) and dose adjustments.
Croatian: Sigurnosni profil lijeka smatra se povoljnim, s nuspojavama koje su podnošljive i koje je moguće kontrolirati suportivnim liječenjem (npr. liječenjem svrbeža) i prilagodbama doza.
English: Ocaliva is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Croatian: Lijek Ocaliva dostupan je u obliku tableta (od 5 i 10 mg) i izdaje se samo na liječnički recept.
English: The measure of effectiveness was based on the number of patients whose blood levels of the substances bilirubin and ALP (markers of liver damage) decreased by at least 15% (for ALP) and below a certain value considered normal (for bilirubin) after 1 year of treatment.
Croatian: Mjerilo učinkovitosti temeljilo se na broju bolesnika u kojih su se razine tvari bilirubin i ALP (pokazatelji oštećenja jetre) u krvi snizile za barem 15 % (za ALP) i ispod određene vrijednosti koja se smatra normalnom (za bilirubin) nakon jedne godine liječenja.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ocaliva have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Ocaliva nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Primary biliary cholangitis is rare, and Ocaliva was designated an ‘orphan medicine' (a medicine used in rare diseases) on 27 July 2010.
Croatian: Primarni bilijarni kolangitis je rijedak, a lijek Ocaliva dobio je status „lijeka za rijetku bolest” 27. srpnja 2010.
English: Side effects reported with Ocaliva are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Ocaliva pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Doses can be reduced or treatment may need to be stopped in patients who experience intolerable itching (a possible side effect with Ocaliva).
Croatian: Doze se mogu smanjiti ili će možda trebati prekinuti liječenje u bolesnika koji iskuse nepodnošljiv svrbež (moguća nuspojava lijeka Ocaliva).
English: An overview of Ocaliva and why it is authorised in the EU
Croatian: Pregled lijeka Ocaliva i zašto je odobren u EU-u
English: As for all medicines, data on the use of Ocaliva is continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Ocaliva kontinuirano se prate.
English: In the majority of cases seen, itching occurred within the first month of treatment and tended to resolve over time while continuing treatment.
Croatian: U većini zabilježenih slučajeva svrbež se pojavio u prvom mjesecu liječenja i s nastavkom liječenja uglavnom bi nestao nakon nekog vremena.
English: It works mainly by attaching to receptors in the liver and gut (farnesoid X receptors) which control the production of bile.
Croatian: Djeluje uglavnom vezivanjem za receptore u jetri i probavnom sustavu (farnezoid X receptor) koji upravljaju stvaranjem žuči.
English: The most common side effects with Ocaliva are itching (which may affect more than 6 in 10 people) and tiredness (which may affect more than 2 in 10 people).
Croatian: Najčešće su nuspojave lijeka Ocaliva svrbež (koji se može javiti u više od 6 na 10 osoba) i umor (koji se može javiti u više od 2 na 10 osoba).
English: This may lead to scarring and liver failure, and may increase the risk of liver cancer.
Croatian: To može uzrokovati ožiljke na jetri i zatajenje jetre te povećati rizik od raka jetre.
English: It is used together with another medicine, ursodeoxycholic acid (UDCA), in patients who do not respond sufficiently to UDCA alone, and on its own in patients who cannot take UDCA.
Croatian: Primjenjuje se zajedno s drugim lijekom, ursodeoksikolnom kiselinom (UDCA) u bolesnika koji ne reagiraju dostatno samo na UDCA i kao monoterapija u bolesnika koji ne mogu uzimati UDCA.
English: Ocaliva was compared with placebo (a dummy treatment) in a main study involving 217 adults with primary biliary cholangitis who either had been taking UDCA for at least 1 year, or who could not take UDCA.
Croatian: Lijek Ocaliva uspoređen je s placebom (prividno liječenje) u okviru glavnog ispitivanja koje je obuhvaćalo 217 odraslih osoba s primarnim bilijarnim kolangitisom koji su uzimali UDCA barem jednu godinu, ili koji nisu mogli uzimati UDCA.
English: The first study is designed to demonstrate the clinical benefit of Ocaliva, while the second study will investigate the benefits of Ocaliva in patients with moderate to severe liver disease.
Croatian: Izvedba prvog ispitivanja osmišljena je za dokazivanje kliničke koristi od lijeka Ocaliva, a u drugom će se ispitivanju istraživati koristi od lijeka Ocaliva u bolesnika s umjerenom do teškom bolešću jetre.
English: Primary biliary cholangitis is an autoimmune condition in which there is gradual destruction of the small bile ducts in the liver.
Croatian: Primarni bilijarni kolangitis autoimuna je bolest kod koje dolazi do postupnog propadanja malih žučnih kanala u jetri.
English: These ducts transport fluid called bile from the liver to the intestines, where it is used to help digest fats.
Croatian: Ti kanali provode tekućinu koja se naziva žuč iz jetre do crijeva, gdje pomaže u probavljanju masti.
English: Ocaliva is used to treat adults with a liver disease known as primary biliary cholangitis.
Croatian: Ocaliva je lijek koji se primjenjuje u liječenju odraslih osoba s bolešću jetre poznate pod nazivom primarni bilijarni kolangitis.
English: How does Ocaliva work?
Croatian: Kako djeluje Ocaliva?
English: The active substance in Ocaliva, obeticholic acid, is a modified form of a bile acid (the main components of bile).
Croatian: Djelatna tvar u lijeku Ocaliva, obetikolna kiselina, modificiran je oblik žučne kiseline (glavnog sastojka žuči).
English: For more information about using Ocaliva, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Ocaliva pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Ocaliva has been shown to reduce the blood levels of bilirubin and ALP in patients with primary biliary cholangitis, including those who could not be treated with UDCA.
Croatian: Utvrđeno je da lijek Ocaliva snižava razine bilirubina i ALP-a u krvi u bolesnika s primarnim bilijarnim kolangitisom, uključujući i bolesnike koji se nisu mogli liječiti UDCA-om.
English: By attaching to these receptors, Ocaliva reduces the production of bile in the liver, preventing it from building up and damaging the liver tissue.
Croatian: Vezivanjem na te receptore lijek Ocaliva smanjuje stvaranje žuči u jetri, čime sprečava nakupljanje žuči i oštećivanje jetrenog tkiva.
English: Reductions in bilirubin and ALP were to an extent which is indicative of an improvement in the condition of the liver.
Croatian: Učinak snižavanja bilirubina i ALP-a upućuje na poboljšanje stanja jetre.
English: As a result of the damage to the ducts, bile builds up in the liver causing damage to the liver tissue.
Croatian: Zbog oštećenja žučnih kanala žuč se nakuplja u jetri i uzrokuje oštećenja jetrenog tkiva.
English: Ocaliva contains the active substance obeticholic acid.
Croatian: Lijek Ocaliva sadržava djelatnu tvar obetikolnu kiselinu.
English: What information is still awaited for Ocaliva?
Croatian: Koje se još informacije očekuju o lijeku Ocaliva?
English: Other information about Ocaliva
Croatian: Ostale informacije o lijeku Ocaliva
English: What benefits of Ocaliva have been shown in studies?
Croatian: Koje su koristi lijeka Ocaliva utvrđene u ispitivanjima?
English: Ocaliva must not be used in patients whose bile ducts are completely blocked.
Croatian: Lijek Ocaliva ne smije se primjenjivati u bolesnika s potpunim začepljenjem žučnih kanala.
English: For the list of all side effects with Ocaliva, see the package leaflet.
Croatian: Popis svih nuspojava lijeka Ocaliva potražite u uputi o lijeku.
English: Intravenous use vial (glass)
Croatian: U venu bočica (staklena)
English: It is used for:
Croatian: Primjenjuje se u:
English: Tarceva is taken at least one hour before or two hours after food.
Croatian: Tarceva se uzima barem jedan sat prije ili dva sata poslije obroka.
English: Further information on Tarceva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Tarceva.
Croatian: Više informacija o lijeku Tarceva nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/Tarceva.
English: Pancreatic cancer
Croatian: Rak gušterače
English: The medicine is available as tablets (25, 100 and 150 mg).
Croatian: Lijek je dostupan u obliku tableta (od 25, 100 i 150 mg).
English: If needed (for example because of side effects), the dose may be reduced in 50-mg steps.
Croatian: Ako je potrebno (primjerice zbog nuspojava), doza se može smanjivati za 50 mg.
English: As a result of this block, the tumour cells can no longer receive the messages needed for growing and for spreading (metastasis).
Croatian: Zbog tog blokiranja, stanice tumora više ne mogu primati poruke potrebne za rast i širenje (metastaziranje).
English: Patients taking Tarceva should stop smoking, as smoking can decrease the amount of the medicine in the blood.
Croatian: Bolesnici koji uzimaju lijek Tarceva moraju prestati pušiti jer pušenje može smanjiti količine lijeka u krvi.
English: What measures are being taken to ensure the safe and effective use of Tarceva?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Tarceva?
English: For NSCLC, the usual dose is 150 mg daily.
Croatian: Kod NSCLC-a uobičajena doza je 150 mg dnevno.
English: Other information about Tarceva
Croatian: Ostale informacije o lijeku Tarceva
English: What is Tarceva and what is it used for?
Croatian: Što je Tarceva i za što se primjenjuje?
English: The medicine contains the active substance erlotinib.
Croatian: Lijek sadrži djelatnu tvar erlotinib.
English: The European Medicines Agency therefore decided that Tarceva's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Tarceva nadmašuju s njim povezane rizike te je preporučila izdavanje odobrenja za stavljanje lijeka u promet.
English: Side effects reported with Tarceva are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Tarceva pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Stable means that the cancer has neither improved nor worsened with chemotherapy (medicines to treat cancer);
Croatian: Stabilna bolest znači da rak nije ni napredovao niti se pogoršao tijekom kemoterapije (terapije protiv raka);
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tarceva have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Tarceva nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: As a result, Tarceva helps to stop the cancer from growing and spreading through the body.
Croatian: Kao rezultat toga, lijek Tarceva pomaže u zaustavljanju rasta i širenja raka u tijelu.
English: As Tarceva seems more effective in patients with pancreatic cancer who develop a rash, treatment should be re-assessed after 4 to 8 weeks if no rash has developed.
Croatian: Budući da se čini da je lijek Tarceva djelotvorniji u bolesnika s rakom gušterače kod kojih se razvio osip, terapiju je potrebno ponovno preispitati nakon četiri do osam tjedana ako se osip nije razvio.
English: Tarceva received a marketing authorisation valid throughout the EU on 19 September 2005.
Croatian: Lijek Tarceva dobio je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 19. rujna
English: An overview of Tarceva and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Tarceva i zašto je odobren u EU-u
English: Tarceva can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the use of cancer medicines.
Croatian: Lijek Tarceva izdaje se samo na liječnički recept, a liječenje mora nadzirati liječnik s iskustvom u primjeni lijekova protiv raka.
English: Erlotinib blocks EGFRs, which can be found on some tumour cells.
Croatian: Erlotinib blokira EGFR-ove koji se mogu naći na površini nekih stanica tumora.
English: As for all medicines, data on the use of Tarceva are continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Tarceva kontinuirano se prate.
English: What are the risks associated with Tarceva?
Croatian: Koji su rizici povezani s lijekom Tarceva?
English: The active substance in Tarceva, erlotinib, belongs to the group ‘EGFR inhibitors'.
Croatian: Djelatna tvar u lijeku Tarceva, erlotinib, ubraja se u skupinu „inhibitora EGFR-a”.
English: • previously untreated patients whose cancer cells have certain changes (‘activating mutations') in the gene for a protein called epidermal growth factor receptor (EGFR);
Croatian: • prethodno neliječenih bolesnika čije stanice raka pokazuju određene promjene („aktivirajuće mutacije”) u genu za bjelančevinu naziva receptor za epidermalni faktor rasta (EGFR);
English: Why is Tarceva authorised in the EU?
Croatian: Zašto je lijek Tarceva odobren u EU-u?
English: For pancreatic cancer, it is 100 mg daily.
Croatian: Kod raka gušterače uobičajena doza je 100 mg dnevno.
English: Tarceva is a cancer medicine used in non-small-cell lung cancer (NSCLC) that is advanced (the cancer has started to spread) or metastatic (it has already spread to other parts of the body).
Croatian: Tarceva je lijek protiv raka koji se primjenjuje za liječenje raka pluća nemalih stanica (NSCLC) koji je uznapredovao (rak se počeo širiti) ili metastazirao (već se proširio na druge dijelove tijela).
English: In NSCLC, Tarceva has been mainly studied in four studies.
Croatian: U bolesnika s NSCLC-om lijek Tarceva uglavnom je ispitivan u okviru četiriju ispitivanja:
English: Tarceva is also used in patients with metastatic pancreatic cancer, in combination with gemcitabine (another cancer medicine).
Croatian: Lijek Tarceva također se primjenjuje u bolesnika s metastatskim rakom gušterače u kombinaciji s gemcitabinom (drugim lijekom protiv raka).
English: However, there was no advantage for patients whose cancer had not spread beyond the pancreas.
Croatian: Međutim, nisu utvrđene koristi u bolesnika u kojih se rak nije proširio izvan gušterače.
English: The study found no advantage to early use of the medicine, as patients treated with Tarceva early in the study did not live longer than those treated with Tarceva later in the study (after the disease had progressed).
Croatian: U ispitivanju nisu utvrđene koristi od rane primjene lijeka jer bolesnici koji su liječeni lijekom Tarceva u ranoj fazi ispitivanja nisu živjeli dulje od onih koji su liječeni lijekom Tarceva u kasnijoj fazi ispitivanja (nakon što je bolest uznapredovala).
English: For more information about using Tarceva, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Tarceva pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Among the patients who took Tarceva, the average survival was 8.6 months in those whose tumours were ‘EGFR IHC-positive' (had EGFRs on the cell surface), and 5.0 months in those whose tumours were EGFR IHC-negative.
Croatian: Među bolesnicima koji su uzimali lijek Tarceva, prosječna stopa preživljenja bila je 8,6 mjeseci u bolesnika s tumorima koji su bili „EGFR-IHC pozitivni” (koji su imali EGFR-ove na površini stanica) i 5,0 mjeseci u bolesnika s EGFR-IHC negativnim tumorima.
English: • patients with EGFR activating mutations whose disease is stable after initial chemotherapy.
Croatian: • bolesnika s aktivirajućim mutacijama EGFR-a čija je bolest stabilna nakon početne kemoterapije.
English: Patients with NSCLC should be tested for EGFR activating mutation before starting Tarceva, unless previous chemotherapy has not worked and other treatments are not suitable.
Croatian: Bolesnike s NSCLC-om treba testirati na aktivirajuću mutaciju EGFR-a prije primjene lijeka Tarceva, osim u slučajevima kad prethodna kemoterapija nije djelovala, a drugi oblici liječenja nisu prikladni.
English: The study compared how long patients survived when Tarceva was used early in the study with how long they survived when Tarceva was used later in the study.
Croatian: U ispitivanju se uspoređivalo koliko su dugo bolesnici preživjeli kada je lijek Tarceva primjenjivan u ranoj fazi ispitivanja, a koliko kada je primjenjivan u kasnijoj fazi ispitivanja.
English: In studies, the most common side effects with Tarceva when used as monotherapy for lung cancer were rash (affecting 75% of patients), diarrhoea (54%), loss of appetite and tiredness (52% each).
Croatian: U ispitivanjima, najčešće nuspojave lijeka Tarceva kada se primjenjivao kao monoterapija za rak pluća bile su osip (zabilježen u 75 % bolesnika), proljev ( 54 %), gubitak apetita i umor (52 %).
English: In the study of Tarceva used in combination with gemcitabine for pancreatic cancer, the most common side effects were tiredness (affecting 73% of patients), rash (69%) and diarrhoea (48%).
Croatian: U ispitivanju primjene lijeka Tarceva u kombinaciji s gemcitabinom u bolesnika s rakom gušterače najčešće nuspojave bile su umor (zabilježen u 73 % bolesnika), osip (69 %) i proljev (48 %).
English: Tarceva can prolong the time the patients live without their disease getting worse and prolong life in some patients.
Croatian: Lijek Tarceva može produžiti razdoblje preživljenja bolesnika bez pogoršanja bolesti te nekima od njih može produžiti život.
English: What benefits of Tarceva have been shown in studies?
Croatian: Koje su koristi od lijeka Tarceva utvrđene u ispitivanjima?